Quick Answer
Silence Therapeutics plc reported Cash and Equivalents of $11.28 million for fiscal year 2025.
Silence Therapeutics plc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.28M | -90.7% |
| 2024 | $121.33M | +76.4% |
| 2023 | $68.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $82.03M | — | +96.5% |
| June 30, 2025 | $41.74M | — | -35.7% |
| March 31, 2025 | $64.89M | — | -46.5% |
| December 31, 2024 | $121.33M | — | — |
- Silence Therapeutics plc showed a decrease of -90.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Silence Therapeutics plc’s cash and equivalents has declined by 83.6% (from $68.79 million to $11.28 million).
- The most recent figure is from Silence Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: